An oral pill could soon serve as an alternative to Wegovy and Ozempic injections after research demonstrated that it significantly reduces weight and enhances blood sugar levels in individuals with obesity and type 2 diabetes.

Created by the pharmaceutical giant Eli Lilly, Orforglipron mimics the action of semaglutide, the key ingredient found in Wigovy and Ozempic, by imitating a hormone known as GLP-1.

In a previous trial, researchers discovered that individuals who were obese but did not have type 2 diabetes could lose an average of approximately 11 percent of their body weight over 72 weeks while using Orforglipron. Although this is less than the 15% typically observed with similar treatments, many find the convenience of taking a pill more appealing. With semaglutide injections, the preference for oral medication becomes clear, as noted by Deborah Horn from the University of Texas.

To assess its effectiveness for those with obesity and type 2 diabetes, Horn and her colleagues enlisted over 1,600 individuals from ten countries, including India, Australia, China, Germany, Brazil, and the United States.

Approximately 900 participants were assigned to receive varying daily doses of orforglipron—low, medium, or high—while the remainder received placebo pills alongside lifestyle guidance.

After 72 weeks, individuals in the high-dose group lost nearly 10 percent on average, with 67 percent of that group achieving over 5 percent weight loss. The middle and low-dose groups recorded around 7 percent and 5 percent reductions, respectively, while the placebo group had less than a 3 percent decrease.

This study reaffirms that Orforglipron results in less weight loss compared to injectable GLP-1 medications; however, it may still enhance health and quality of life. Stefan Trapp from University College London, who did not participate in the study, remarked, “Even a modest 5% weight loss generally leads to clear benefits, such as increased exercise capacity, lifestyle changes, and reduced risk of other illnesses.”

Moreover, participants receiving high doses experienced an average drop of nearly 2 percent in blood sugar levels, with approximately 75 percent reaching levels typically aimed for diabetics, Horn shared. Conversely, those on lower doses saw a mere 0.1% reduction, while the placebo group exhibited no significant change.

Roughly 10% of the individuals taking high and medium doses had to discontinue use due to side effects like nausea, vomiting, and diarrhea—nearly double the occurrence seen in the low and placebo groups. Nonetheless, most participants deemed the side effects manageable, according to Horn. “The side effects were standard for other GLP-1 injectable medications,” she explained.

Horn mentioned that Eli Lilly anticipates the FDA will approve the drug for obesity and type 2 diabetes by early next year. As a physician, she hopes for approval of all three doses to provide patients with options to optimize their health while minimizing side effects.

Orforglipron does not necessitate refrigeration or syringes, which may lower manufacturing, storage, and distribution costs compared to injectable GLP-1 drugs. This, along with the elimination of injection-related discomfort, could enhance access to GLP-1 weight-loss drugs, which are currently costly and hard to obtain in many low- and middle-income nations, Trapp noted.